194 related articles for article (PubMed ID: 32310325)
21. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
[TBL] [Abstract][Full Text] [Related]
22. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
Hudelist G; Köstler WJ; Czerwenka K; Kubista E; Attems J; Müller R; Gschwantler-Kaulich D; Manavi M; Huber I; Hoschützky H; Zielinski CC; Singer CF
Int J Cancer; 2006 Mar; 118(5):1126-34. PubMed ID: 16161043
[TBL] [Abstract][Full Text] [Related]
23. Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.
Takahashi H; Tada Y; Saotome T; Akazawa K; Ojiri H; Fushimi C; Masubuchi T; Matsuki T; Tani K; Osamura RY; Hirai H; Yamada S; Kawakita D; Miura K; Kamata SE; Nagao T
J Clin Oncol; 2019 Jan; 37(2):125-134. PubMed ID: 30452336
[TBL] [Abstract][Full Text] [Related]
24. [Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma].
Otsuka K; Imanishi Y; Habu N; Sato Y; Shigetomi S; Fujii R; Sakamoto K; Tomita T; Fujii M; Kameyama K; Ogawa K
Nihon Jibiinkoka Gakkai Kaiho; 2013 Sep; 116(9):1024-32. PubMed ID: 24191589
[TBL] [Abstract][Full Text] [Related]
25. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
26. Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors.
Can NT; Lingen MW; Mashek H; McElherne J; Briese R; Fitzpatrick C; van Zante A; Cipriani NA
Head Neck Pathol; 2018 Mar; 12(1):95-104. PubMed ID: 28681314
[TBL] [Abstract][Full Text] [Related]
27. Combined androgen deprivation therapy in recurrent androgen-receptor-positive salivary duct carcinoma - a case report and review of the literature.
Poxleitner P; Shoumariyeh K; Steybe D; Hupfer V; Voss PJ; Rawluk J; Ermer M; Miething C; Schmelzeisen R; Duyster J
J Stomatol Oral Maxillofac Surg; 2020 Nov; 121(5):599-603. PubMed ID: 31904529
[TBL] [Abstract][Full Text] [Related]
28. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study.
Dori S; Vered M; David R; Buchner A
J Oral Pathol Med; 2002 Sep; 31(8):463-7. PubMed ID: 12220353
[TBL] [Abstract][Full Text] [Related]
29. Case report: ado-trastuzumab as second-line treatment in HER2 positive salivary duct carcinoma.
Taha T; Billan S
Anticancer Drugs; 2022 Jan; 33(1):e760-e763. PubMed ID: 34387606
[TBL] [Abstract][Full Text] [Related]
30. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance.
Nagao T; Gaffey TA; Visscher DW; Kay PA; Minato H; Serizawa H; Lewis JE
Am J Surg Pathol; 2004 Mar; 28(3):319-26. PubMed ID: 15104294
[TBL] [Abstract][Full Text] [Related]
31. Ten years of using adjuvant trastuzumab in breast cancer in Serbia - Single institution experience.
Cvetanovic A; Filipovic S; Zivkovic N; Popovic L; Kostic M; Djordjevic M; Karanikolic A; Krtinic D
J BUON; 2018; 23(2):353-360. PubMed ID: 29745076
[TBL] [Abstract][Full Text] [Related]
32. Targeting human EGFR 2 (HER2) in salivary gland carcinoma.
Wotman M; El-Naggar A; Ferrarotto R
Expert Rev Anticancer Ther; 2023 Jun; 23(6):573-582. PubMed ID: 37114470
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study.
Ali S; Hendry J; Le D; Mondal PK; Sami A; Chalchal H; Haider K; Ahmed O; El-Gayed A; Wright P; Pauls M; Johnson K; Ahmed S
Sci Rep; 2022 Jan; 12(1):1068. PubMed ID: 35058536
[TBL] [Abstract][Full Text] [Related]
35. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
Boon E; Bel M; van Boxtel W; van der Graaf WTA; van Es RJJ; Eerenstein SEJ; Baatenburg de Jong RJ; van den Brekel MWM; van der Velden LA; Witjes MJH; Hoeben A; Willems SM; Bloemena E; Smit LA; Oosting SF; ; Jonker MA; Flucke UE; van Herpen CML
Int J Cancer; 2018 Aug; 143(4):758-766. PubMed ID: 29492965
[TBL] [Abstract][Full Text] [Related]
36. Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Poggio F; Puglisi F; Bernardo A; Montemurro F; Poletto E; Pozzi E; Rossi V; Risi E; Lai A; Zanardi E; Sini V; Ziliani S; Minuti G; Mura S; Grasso D; Fontana A; Del Mastro L
Oncologist; 2015 Aug; 20(8):880-9. PubMed ID: 26099741
[TBL] [Abstract][Full Text] [Related]
37. Sustained response of HER2-positive metastatic salivary adenocarcinoma, not otherwise specified, treated with trastuzumab.
Ghazali N; Parker L; Settle K; Lubek JE
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Sep; 122(3):292-9. PubMed ID: 27289263
[TBL] [Abstract][Full Text] [Related]
38. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
[TBL] [Abstract][Full Text] [Related]
39. A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.
Gilbert MR; Sharma A; Schmitt NC; Johnson JT; Ferris RL; Duvvuri U; Kim S
JAMA Otolaryngol Head Neck Surg; 2016 May; 142(5):489-95. PubMed ID: 26939990
[TBL] [Abstract][Full Text] [Related]
40. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
